{"id":33473,"date":"2025-01-28T14:39:00","date_gmt":"2025-01-28T14:39:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4605931_AE05931_0"},"modified":"2025-01-28T14:39:00","modified_gmt":"2025-01-28T14:39:00","slug":"getinge-year-end-report-2024-strong-order-intake-and-increased-sales-contributed-to-sharp-improvement-in-margins","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=33473","title":{"rendered":"Getinge Year End Report 2024: Strong order intake and increased sales contributed to sharp improvement in margins"},"content":{"rendered":"

GOTHENBURG, Sweden<\/span><\/span>, Jan. 28, 2025<\/span><\/span> \/PRNewswire\/ — “In 2024, Getinge had record sales and we finished off the year with a strong quarter. Both order intake and net sales increased significantly, also organically, with positive performance in all regions”, says Mattias Perjos, CEO of Getinge.<\/b><\/p>\n

Growth was particularly strong in ventilators, where Getinge is benefiting from the consolidation in the market. Furthermore, consumables in ECLS in Acute Care Therapies and Sterile Transfer in Life Science, showed solid performance. <\/p>\n

Paragonix Technologies, Inc., which was acquired in Q3 2024, reported impressive growth in the quarter. The KidneyVault portable renal perfusion system, which addresses the largest organ transplant market in terms of volume, received FDA 510(k) clearance. This means that Paragonix now has unique breadth in its product portfolio, which encompasses all major organ categories.<\/p>\n

Getinge’s focus on structural measures to increase productivity and cost efficiency contributed to the operating margin strengthening significantly compared with Q4 2023.<\/p>\n

“The strong cash flow and earnings in the quarter highlight the leverage we have in terms of profitability when we achieve higher sales,” says Mattias Perjos.<\/p>\n

After the board’s review, Getinge has initiated a process with the strategic intention to phase-out the Surgical Perfusion product category, to further strengthen the company’s long-term growth and profitability. This would contribute marginally positive to adjusted EBITA from 2025 and gradually increase onwards, thanks to reallocation of resources to attractive areas such as ECLS and Transplant Care. Getinge’s market share in Surgical Perfusion is not satisfactory and the market growth is limited.<\/p>\n

Despite geopolitical uncertainty and potential trade barriers, demand is expected to be relatively stable, with long-term care needs and hospitals’ willingness to invest as continued strong drivers. <\/p>\n

“In 2024, we have demonstrated that we are well positioned in prioritized product categories for our customers. This means that we have a positive outlook on 2025 and expect organic sales growth of 2-5% for the full year,” says Mattias Perjos.<\/p>\n

October \u2013 December 2024<\/span> in brief<\/b><\/p>\n